News

Novo Nordisk's former chief makes comeback to steer choice of new CEO
Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...
Novo Nordisk joins finance’s great one-hit wonders
In the near term, commercial efforts might raise the chances that new patients are prescribed Novo Nordisk’s drug, assuming ...
Pulmonology Advisor7h
Novo Nordisk, US Biotech Company Team Up to Create Obesity Pills
Novo Nordisk has contracted California-based biotech Septerna to develop oral pills that target G protein-coupled receptors.
Novo Nordisk Foundation pledges $57 million to WHO amid US funding gap
The Novo Nordisk Foundation has pledged up to DKK 380 million ($57.76 million) to the World Health Organization (WHO) to ...
STAT13h
In the war for GLP-1 patients, Novo Nordisk leans on telehealth
Novo Nordisk's limited-time coupon on Wegovy was simultaneously promoted by telehealth companies Ro and Wegovy ...
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...
Explore more
CEO of Novo Nordisk, maker of weight loss drug Wegovy, to step down in wake of share price drop
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.
$2B Novo Nordisk deal shakes up pharma market
Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...